Sylvie Lorenzen

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

Florian Lordick, Katja Ott, Bernd‐Joachim Krause et al. · The Lancet Oncology · 2007 · 803 citations

Esophagus, Oesophagogastric Junction, Esophageal Cancer +9

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 713 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +12

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

Salah‐Eddin Al‐Batran, Thorsten Oliver Goetze, Daniel Mueller et al. · BMC Cancer · 2017 · 218 citations · Full text

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2023 · 173 citations